Evidence map›Paper›PMID 39638560›Full record

ArticleGenome research2025

Rearrangements of viral and human genomes at human papillomavirus integration events and their allele-specific impacts on cancer genome regulation.

Vanessa L Porter, Michelle Ng, Kieran O'Neill, Signe MacLennan, Richard D Corbett, Luka Culibrk, Zeid Hamadeh, Marissa Iden, Rachel Schmidt, Shirng-Wern Tsaih and 17 more

Abstract read
In one paragraph

Article in Genome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Vanessa L PorterCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0002-7167-4884
Michelle NgCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0001-5113-3733
Kieran O'NeillCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0001-7609-5905
Signe MacLennanCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0009-0000-0021-375X
Richard D CorbettCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Luka CulibrkCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0003-1208-1920
Zeid HamadehCytogenomics Laboratory, Vancouver General Hospital, Vancouver, British Columbia V5Z 1N1, Canada.
Marissa IdenDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.ORCID 0000-0003-3383-1751
Rachel SchmidtDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.
Shirng-Wern TsaihDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.ORCID 0000-0002-9836-4659
Carolyn NakisigeUganda Cancer Institute, Kampala, Uganda.
Martin OrigaUganda Cancer Institute, Kampala, Uganda.
Jackson OremUganda Cancer Institute, Kampala, Uganda.
Glenn ChangCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0003-4008-1725
Jeremy FanCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Ka Ming NipCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0002-1574-3363
Vahid AkbariCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0001-8005-7776
Simon K ChanCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
James HopkinsCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Richard A MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Eric ChuahCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Karen L MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0002-0905-2742
Inanc BirolCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0003-0950-7839
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada.ORCID 0000-0003-3394-2208
Janet S RaderDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.ORCID 0000-0001-7031-3385
Marco A MarraCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia V5Z 4S6, Canada; mmarra@bcgsc.ca.ORCID 0000-0001-7146-7175

Funding

Enlisting HPV integration events to illuminate drivers and target treatment in invasive cervical cancerR01CA262198 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Janet S. Rader · 2022 to 2026
$2.1M
Defining HPV integration sites of unknown significance in invasive cervical cancerR21CA241013 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI RADER, JANET S. · 2020 to 2020
$401k
NCI NIH HHS R01 CA262198NCI NIH HHS R21 CA241013
6 · The paper itself

Abstract

Human papillomavirus (HPV) integration has been implicated in transforming HPV infection into cancer. To resolve genome dysregulation associated with HPV integration, we performed Oxford Nanopore Technologies long-read sequencing on 72 cervical cancer genomes from a Ugandan data set that was previously characterized using short-read sequencing. We find recurrent structural rearrangement patterns at HPV integration events, which we categorize as del(etion)-like, dup(lication)-like, translocation, multi-breakpoint, or repeat region integrations. Integrations involving amplified HPV-human concatemers, particularly multi-breakpoint events, frequently harbor heterogeneous forms and copy numbers of the viral genome. Transcriptionally active integrants are characterized by unmethylated regions in both the viral and human genomes downstream from the viral transcription start site, resulting in HPV-human fusion transcripts. In contrast, integrants without evidence of expression lack consistent methylation patterns. Furthermore, whereas transcriptional dysregulation is limited to genes within 200 kb of an HPV integrant, dysregulation of the human epigenome in the form of allelic differentially methylated regions affects megabase expanses of the genome, irrespective of the integrant's transcriptional status. By elucidating the structural, epigenetic, and allele-specific impacts of HPV integration, we provide insight into the role of integrated HPV in cervical cancer.

Indexed as

Gene RearrangementGenome, HumanGenome, ViralPapillomaviridaePapillomavirus InfectionsUterine Cervical NeoplasmsVirus IntegrationAllelesDNA MethylationFemaleGene Expression Regulation, NeoplasticHuman Papillomavirus VirusesHumans

Identifiers

PMID39638560
PMCPMC12047271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.